| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Nva-OH is classified as an amino acid derivative with applications in peptide synthesis. It does not have a specific biological receptor target; rather, it functions as a protecting group reagent for introducing norvaline into synthetic peptides. The Fmoc group protects the amino group during chain assembly and is removed under mild basic conditions. The norvaline residue can affect peptide conformation and biological activity when incorporated into bioactive sequences.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity of Fmoc-Nva-OH is primarily as a peptide synthesis reagent. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. They affect the release of anabolic hormones, the availability of fuel for activity, and mental performance under pressure. Fmoc-Nva-OH itself is not biologically active in cell-based assays; its utility is in the preparation of norvaline-containing peptides for subsequent biological evaluation. |
| ln Vivo |
There is no specific in vivo activity data for Fmoc-Nva-OH as it is a protected amino acid building block used in research. The compound is not administered in vivo in its intact form. Peptides incorporating norvaline residues synthesized using Fmoc-Nva-OH may be evaluated in animal models for various biological activities depending on the peptide sequence. Norvaline is a non-proteinogenic amino acid that can be used to probe enzyme specificity and protein function in vivo.
|
| Enzyme Assay |
Standard protocols for Fmoc-amino acids involve activation and coupling in SPPS. Fmoc-Nva-OH (0.5-1.0 mmol) is dissolved in DMF with coupling reagents such as HATU or HBTU (0.95-1.0 equiv) and DIPEA (2.0-2.5 equiv). The activated solution is added to the resin-bound peptide and agitated for 1-2 hours. Coupling completion is monitored by Kaiser test or HPLC. Deprotection of the Fmoc group is achieved with 20% piperidine in DMF (2 × 5-10 min). Purity is verified by HPLC (≥98%).
|
| Cell Assay |
In vitro cell-based assays using Fmoc-Nva-OH are not applicable as it is a peptide synthesis building block, not a cell-permeable compound. However, norvaline-containing peptides synthesized with this reagent can be tested in cell culture. Peptides are dissolved in DMSO or cell culture medium, filtered sterile, and added to cells at concentrations ranging from 0.1-100 µM. Cells are incubated for 24-72 hours, and endpoints such as cell viability, proliferation, or signaling pathway activation are measured using standard assays.
|
| Animal Protocol |
Animal studies with Fmoc-Nva-OH are not conducted as the compound is a research reagent. Norvaline-containing peptides synthesized using this building block may be evaluated in vivo. Typical protocols involve administration of the peptide in appropriate formulations via injection or oral gavage. Blood samples are collected for PK analysis, and tissues are harvested for histopathological or biomarker analysis. Dosing regimens depend on the peptide's intended therapeutic application and are determined empirically.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fmoc-Nva-OH are not applicable to the compound itself as it is not a drug. The compound has a molecular weight of 339.39 g/mol, formula C₂₀H₂₁NO₄, and LogP of 4.61. It is soluble in DMF and other organic solvents for peptide synthesis. The Fmoc group is removed under basic conditions during synthesis. The resulting norvaline-containing peptides may have altered PK properties due to the non-natural amino acid residue, potentially affecting metabolic stability and bioavailability.
|
| Toxicity/Toxicokinetics |
Limited toxicity data is available for Fmoc-Nva-OH as it is a research chemical. Standard laboratory safety practices should be followed when handling. The compound is not intended for human use. Acute toxicity is expected to be low. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. Proper personal protective equipment should be worn.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Fmoc-Nva-OH (CAS#: 135112-28-6) is also known as (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)pentanoic acid and Fmoc-L-norvaline. Its molecular weight is 339.39 and formula is C₂₀H₂₁NO₄. The compound has a purity of ≥98% by HPLC and an optical rotation of -22 to -18° (c=2, DMF). It is a standard reagent for solid-phase peptide synthesis. It has no approved therapeutic indications and is not in clinical trials.
|
| Molecular Formula |
C20H21NO4
|
|---|---|
| Molecular Weight |
339.38504
|
| Exact Mass |
339.147
|
| CAS # |
135112-28-6
|
| PubChem CID |
7016885
|
| Appearance |
White to off-white powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
557.9±33.0 °C at 760 mmHg
|
| Melting Point |
151-153ºC
|
| Flash Point |
291.2±25.4 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
4.61
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCC[C@H](NC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O)C(O)=O
|
| InChi Key |
JBIJSEUVWWLFGV-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C20H21NO4/c1-2-7-18(19(22)23)21-20(24)25-12-17-15-10-5-3-8-13(15)14-9-4-6-11-16(14)17/h3-6,8-11,17-18H,2,7,12H2,1H3,(H,21,24)(H,22,23)/t18-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
|
| Synonyms |
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)pentanoic acid; Fmoc-Nva-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
